Vertical: CNMBase Year: 2025
Market Size (2025)
$220.40M
Projected (2032)
$295.24M
CAGR (2022–2032)
4.9%
Key Players
10+
Market Overview
The Global Polyethyleneimine Market was valued at USD 220.40 Million in 2025 and is projected to reach USD 295.24 Million by 2032, registering a CAGR of 4.15% over 2026–2032. The market has expanded steadily from USD 182.48 Million in 2022, and is expected to add USD 74.84 Million in absolute value between 2025 and 2032.
Polyethyleneimine (PEI) is a highly cationic, amine-rich polymer used wherever strong adhesion to negatively charged surfaces is needed. Its largest outlets are papermaking chemistry (retention, drainage, fixing and wet-strength), water and wastewater treatment (flocculation and metal binding), and gene delivery, where linear PEI is a standard reagent for transient transfection in viral vector and recombinant protein manufacturing. A long tail of uses, including adhesion promoters for packaging films and coatings, inks, detergents, epoxy curing, CO₂-capture sorbents and battery and electronics materials, makes up the "Others" category. Demand is shaped by packaging and tissue paper output, tighter discharge standards for industrial and municipal water, and the scale-up of cell and gene therapy manufacturing.
Key Findings
Product type: Branched PEI is the largest product type, at USD 165.30 Million in 2025 (75.00% share). Linear PEI is the fastest-growing type, with a CAGR of 5.16% over 2026–2032.
Application: Pulp & Paper is the largest application, at USD 77.14 Million in 2025 (35.00% share). Gene Delivery & Biotech is the fastest-growing application, with a CAGR of 5.97%.
Region: Asia Pacific leads the market with USD 96.98 Million in 2025 (44.00% share). Middle East & Africa is the fastest-growing region, with a CAGR of 5.54%.
Country: China is the largest country market, at USD 46.55 Million in 2025, just ahead of the U.S. at USD 45.18 Million. India is the fastest-growing country, with a CAGR of 7.66%.
Absolute growth: Asia Pacific accounts for USD 38.84 Million of the USD 74.84 Million added globally between 2025 and 2032, more than North America and Europe combined.
Segmentation Summary
By product type, branched PEI dominates with USD 165.30 Million in 2025 (75.00%), reflecting its use as a liquid, water-soluble process chemical in paper, water treatment, adhesives and coatings. Linear PEI, at USD 55.10 Million (25.00%), is smaller but grows faster (5.16% versus 3.79%) because it is the preferred grade for transfection and other high-purity, life-science uses.
By application, pulp & paper (USD 77.14 Million, 35.00%) and Others (USD 66.12 Million, 30.00%) are the two largest categories. Water treatment (USD 44.08 Million, 20.00%) and gene delivery & biotech (USD 33.06 Million, 15.00%) are the two fastest-growing, at CAGRs of 5.20% and 5.97% respectively. The application mix is therefore shifting toward higher-value uses.
By region, Asia Pacific (44.00% share in 2025) is both the largest market and the main source of new demand, led by China, Japan and India. North America and Europe each account for USD 55.10 Million in 2025, but grow more slowly (3.55% and 3.25%). Latin America (5.09%) and the Middle East & Africa (5.54%) are small but grow above the global average.
Competitive Landscape Summary
The market is moderately consolidated, with two distinct competitive arenas. Industrial branched PEI is supplied mainly by a few integrated producers with ethyleneimine capability, led by BASF (Lupasol) and Nippon Shokubai (EPOMIN), along with a growing group of Chinese producers such as Wuhan Qianglong New Chemical Materials. Transfection-grade and high-purity PEI is a more fragmented, faster-growing field. Sartorius, through its 2023 acquisition of Polyplus (PEIpro, FectoVIR-AAV), is the leader. Polysciences and its Kyfora Bio brand (PEI MAX, MAXgene GMP), Merck KGaA (Sigma-Aldrich PEI Prime) and Yeasen Biotechnology are the main challengers. Thermo Fisher Scientific, FUJIFILM Wako and Tokyo Chemical Industry serve research demand through global catalogues. Competition centres on molecular weight range, purity and GMP documentation, technical service and supply security. Since 2022, competitors have pursued acquisitions, GMP capacity expansion and regulatory filings such as US FDA Drug Master Files.
Challenges and Opportunities
The main challenges are structural. Ethyleneimine (aziridine), the monomer for branched PEI, is acutely toxic and classified as a carcinogen, so very few companies can make it, and supply security depends on a handful of plants. PEI also competes with lower-cost cationic polymers such as polyvinylamine, polyamidoamine-epichlorohydrin (PAE) resins, polyDADMAC and cationic polyacrylamides, and in gene delivery with lipid-based reagents and stable producer cell lines. Graphic paper output continues to decline in mature markets, which limits volume growth in the largest application.
The opportunities lie in higher-value grades. GMP-grade linear PEI for viral vector manufacturing, PEI-based sorbents for carbon capture, PEI-modified membranes and adsorbents for heavy-metal and micropollutant removal, and adhesion promoters for recyclable mono-material packaging all command premium pricing. Paper-based packaging replacing plastics also supports retention-aid and wet-strength demand, particularly in Asia Pacific and Latin America.
Future Outlook
The market is expected to grow from USD 231.35 Million in 2026 to USD 295.24 Million in 2032. Growth will come increasingly from specialty and life-science uses and from emerging economies. By 2032, linear PEI is expected to reach USD 79.13 Million, gene delivery & biotech USD 50.19 Million and water treatment USD 63.48 Million. Suppliers that secure monomer supply, invest in high-purity and GMP-compliant production, and build regional technical service in Asia will be best placed to capture this growth.
The Polyethyleneimine Market market is projected to grow at a CAGR of 4.9% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Polyethyleneimine (PEI), also called polyaziridine or poly(iminoethylene), is a synthetic water-soluble polymer made of repeating –CH₂–CH₂–NH– units (CAS No. 9002-98-6). Every third atom of the backbone is a nitrogen that can be protonated, which gives PEI the highest cationic charge density of any commercial polymer. This charge density drives its performance: strong adsorption onto cellulose fibres, anionic colloids, metal surfaces and nucleic acids, and high reactivity toward epoxides, isocyanates, aldehydes and carbon dioxide.
Two structural forms are commercially relevant:
Branched PEI is made by acid-catalysed ring-opening polymerisation of ethyleneimine (aziridine). It contains primary, secondary and tertiary amine groups and is usually supplied as a viscous, water-soluble liquid or aqueous solution, with molecular weights from below 1,000 g/mol to above 1,000,000 g/mol.
Linear PEI contains almost exclusively secondary amines. It is typically made by hydrolysing poly(2-alkyl-2-oxazoline) precursors and supplied as a solid or salt (for example, hydrochloride) form. It is the preferred grade for transient transfection and other life-science uses.
Included in the scope: branched and linear PEI homopolymers sold as liquids, solutions, powders or salts, including technical, high-purity, research and GMP grades, and PEI grades with minor functional modification sold under PEI product lines. The market is valued at the manufacturer and first-seller level across pulp & paper, water treatment, gene delivery & biotech and other end uses.
Excluded from the scope: ethyleneimine monomer sold as such; chemically distinct cationic polymers such as polyvinylamine, polyDADMAC, cationic polyacrylamide and PAE resins; finished transfection kits and formulated end products where PEI is a minor ingredient, valued at the formulated-product level; and PEI produced and consumed captively in research laboratories.
Scope of the Study
The study covers the Global Polyethyleneimine Market by product type, application and region, with country-level analysis within each region. Market values are in USD Million for the historic years 2022–2024, the base year 2025 and the forecast years 2026–2032. Growth rates are expressed as the compound annual growth rate (CAGR) for 2026–2032.
Research Objectives
To estimate the size of the global polyethyleneimine market for 2022–2025 and forecast it for 2026–2032 in USD Million.
To analyse the market by product type (branched and linear) and identify how grade, molecular weight and purity requirements shape demand.
To quantify demand from pulp & paper, water treatment, gene delivery & biotech and other applications, and assess the growth outlook for each.
To assess regional and country-level demand across North America, Europe, Asia Pacific, Latin America and the Middle East & Africa.
To identify the drivers, restraints, opportunities, trends and challenges affecting the market, including monomer supply security and chemical safety regulation.
To analyse the value chain from ethylene and ethanolamine feedstocks to PEI producers, distributors and end users.
To profile the leading PEI producers and suppliers and track their developments since 2022.
To assess the regulatory landscape for PEI and its monomer across major regions.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured, multi-stage process that combined secondary research, primary validation with industry participants, and quantitative modelling. The process began with defining the market, the product scope and the segmentation framework. Secondary research then established a baseline of production capacity, trade flows, end-use consumption and pricing. This baseline was tested and refined through discussions with producers, distributors and end users. Market size was estimated using both top-down and bottom-up approaches, triangulated, and projected over the forecast period using a driver-based model.
Market definition and scoping
Secondary research and data collection
Primary research and validation
Market size estimation and data triangulation
Forecasting and scenario review
Quality review and final reporting
Secondary Research
Secondary research drew on sources relevant to the PEI value chain, from monomer production through end-use consumption:
Industry associations: pulp and paper bodies (for example, the Confederation of European Paper Industries and the American Forest & Paper Association), water industry associations, the European Chemical Industry Council (Cefic), the American Chemistry Council, and biomanufacturing groups such as the Alliance for Regenerative Medicine.
Government and regulatory bodies: the European Chemicals Agency (REACH registration dossiers and CLP classifications), the U.S. Environmental Protection Agency (TSCA inventory), the U.S. Food and Drug Administration (indirect food additive regulations and gene therapy guidance), OSHA, China's Ministry of Ecology and Environment, and Japan's chemical inventory authorities.
Trade and production statistics: UN Comtrade, Eurostat, the U.S. Census Bureau and the U.S. International Trade Commission, used for trade in polyamines and related HS codes, and national pulp, paper and water statistics.
Company filings: annual reports, investor presentations, capacity announcements, product literature and technical data sheets from PEI producers and life-science reagent suppliers.
Trade journals and technical literature: papermaking, water treatment and bioprocessing journals, patent databases and peer-reviewed studies on PEI chemistry, transfection and carbon capture.
Paid databases: subscription chemical market, trade and company databases used to cross-check volumes, prices and financial data.
Primary Research
Primary research validated the secondary findings and filled gaps on pricing, grade mix, customer behaviour and future demand. Interviews were conducted on both the supply side and the demand side of the market.
Supply side: product and business managers at PEI and ethyleneimine producers, R&D and technical service specialists, regional sales managers, and executives at chemical distributors and life-science reagent suppliers.
Demand side: process chemists and procurement managers at paper and board mills, water treatment operators and chemical formulators, bioprocess and viral vector manufacturing scientists at biopharmaceutical companies and CDMOs, and formulators in adhesives, coatings and inks.
Objectives: to validate market size and segment splits, understand pricing by grade and region, assess substitution threats, identify capacity and supply constraints, and test growth assumptions for each application and region.
Market Size Estimation
Top-down approach. The global market was estimated from the available supply of PEI, built up from the production capacity and utilisation of known ethyleneimine and PEI producers, adjusted for captive use, inventory changes and trade. The total was then allocated to product types, applications and regions using shares derived from company disclosures, trade data and expert input.
Bottom-up approach. Demand was estimated for each application and country by combining activity indicators with PEI consumption intensity. These indicators include paper and board output, treated water volumes, viral vector production capacity and adhesive and coating volumes. Volumes were converted to value using grade-specific average selling prices and aggregated to regional and global totals.
Data triangulation. The top-down and bottom-up estimates were compared at the global, regional and segment levels. Differences were reconciled through further primary research and by checking against company revenue disclosures, so that every segment, region and country total is consistent with the overall market value.
Forecasting Methodology
Forecasts for 2026–2032 were built with a driver-based model applied to each application and region, then aggregated. The main factors considered were:
Macroeconomic indicators: GDP, industrial production and manufacturing output by country.
End-use indicators: packaging and tissue paper production, municipal and industrial water treatment investment, and cell and gene therapy pipelines and viral vector manufacturing capacity.
Supply factors: announced capacity additions, monomer availability and the entry of new regional producers.
Price trends: feedstock (ethylene, ethanolamines) and energy costs, and the shift toward higher-value grades.
Regulatory developments affecting PEI, ethyleneimine and competing chemistries.
Base-case growth rates were stress-tested against high and low scenarios and validated with industry participants before the final forecasts were set.
Assumptions and Limitations
Market values are in nominal US dollars, using average annual exchange rates for the historic and base years and constant exchange rates for the forecast period.
The forecast assumes no major disruption to ethyleneimine supply, such as a prolonged outage at a major monomer plant, and no outright regulatory ban on PEI in any major market.
Macroeconomic conditions are assumed to follow consensus projections from major international institutions.
Prices for research and GMP grades vary widely by pack size and supplier, so value estimates for gene delivery & biotech are based on weighted average selling prices.
Captive consumption of PEI within integrated chemical companies is estimated from available indicators and may carry a wider margin of uncertainty.
The "Others" application aggregates many smaller end uses, so its growth outlook represents a blended average.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The Global Polyethyleneimine Market is moderately consolidated at the industrial level and more fragmented in life-science grades. Branched PEI production depends on access to ethyleneimine monomer, which only a few companies make because of the monomer's hazard profile and the specialised infrastructure it requires. As a result, a small number of integrated producers, notably BASF and Nippon Shokubai, supply a large part of global industrial demand, and Chinese producers are building a growing domestic presence.
Transfection-grade and high-purity PEI, mainly linear PEI, is a separate competitive arena with more participants. Life-science companies compete on transfection performance, lot-to-lot consistency, GMP compliance, regulatory documentation such as Drug Master Files, and technical support for viral vector process development. Competition in this arena has intensified since 2022 through acquisitions, including Sartorius's purchase of Polyplus and Merck KGaA's purchase of Mirus Bio, through GMP capacity investments, and through the entry of Chinese GMP reagent suppliers. In industrial grades, competition centres on price, molecular weight range, supply reliability and application support.
Key Player Positioning
Companies are grouped by their qualitative position in the market, based on their PEI portfolio breadth, production capability, regional reach and strategic activity.
Leaders: BASF SE, Nippon Shokubai and Sartorius (Polyplus). The first two are integrated industrial PEI producers with the broadest molecular weight ranges and global supply. Sartorius leads in GMP transfection-grade PEI reagents.
Challengers: Polysciences (Kyfora Bio), Merck KGaA and Yeasen Biotechnology. They have strong positions in research and GMP-grade linear PEI and are actively investing in bioprocessing capabilities.
Niche players: Thermo Fisher Scientific, FUJIFILM Wako, Tokyo Chemical Industry and Wuhan Qianglong New Chemical Materials. The first three serve research demand through global catalogues; Wuhan Qianglong focuses on domestic Chinese industrial demand.
BASF SE (Leader)
Overview: BASF SE, headquartered in Ludwigshafen, Germany, and founded in 1865, is the world's largest diversified chemical company. Its polyethyleneimine range is marketed under the Lupasol brand (and Polymin for paper applications) through businesses in the Nutrition & Care segment. It is backed by BASF's integrated Verbund amine chemistry.
Latest reported revenue: EUR 59.7 billion (FY2025).
Relevant products: Lupasol branched PEI in water-free and aqueous grades across a broad molecular weight range, including Lupasol G 20 Waterfree, Lupasol P, Lupasol SK, Lupasol PN 40 and Lupasol SNA. Uses include adhesion promotion, tie-bonds in lamination inks, crosslinking and flocculation. Related alkoxylated PEI includes Sokalan HP 20 for detergents.
Key developments:
September 2024: Launched its "Winning Ways" corporate strategy, designating Nutrition & Care, home of the Lupasol business, as a core segment.
April 2024: Extended its biomass-balanced EcoBalanced portfolio for European detergent, cleaning and industrial formulators to about 20 products.
October 2025: Reaffirmed its 2028 financial targets at a Capital Market Update, alongside continued portfolio pruning.
Strategy: BASF focuses on integrated core businesses and cost discipline, using its backward integration into amines to keep Lupasol the broadest industrial PEI range worldwide, supported by distribution partners such as ChemPoint.
Nippon Shokubai Co., Ltd. (Leader)
Overview: Nippon Shokubai, headquartered in Osaka, Japan, and founded in 1941, produces acrylic acid, superabsorbent polymers, ethylene oxide and glycols, and a wide range of functional chemicals. It makes its water-soluble cationic PEI, EPOMIN, at its Kawasaki plant, with backward integration into ethylene oxide-based intermediates.
Latest reported revenue: JPY 399.9 billion (FY2025, year ended March 2026).
Relevant products: The EPOMIN series spans molecular weights from about 300 to 100,000 (for example SP-003, SP-006, SP-012, SP-018, SP-200, HM-2000, P-1050 and the ultra-high-molecular-weight P-3000). Applications include laminate anchor coats, plating, adhesives, inks, paper, water treatment and enzyme immobilisation.
Key developments:
April 2023: Reorganisation took effect, including a new Water & Environment Solutions business department.
April 2025: Announced Mid-Term Management Plan 2027 (FY2025–2027), targeting more than 50% of profit from its Solutions businesses and JPY 245 billion of capital expenditure.
Strategy: Nippon Shokubai is shifting its profit mix toward specialty "Solutions" businesses, positioning EPOMIN as a high-charge-density functional polymer for coatings, electronics and environmental applications in Asia and export markets.
Sartorius AG (Polyplus) (Leader)
Overview: Sartorius, headquartered in Göttingen, Germany, and founded in 1870, is a leading supplier of bioprocess and laboratory equipment and consumables. Its subsidiary Sartorius Stedim Biotech acquired Polyplus in 2023. Polyplus was founded in Strasbourg, France, in 2001 and is a leading supplier of PEI-based transfection reagents for viral vector manufacturing.
Latest reported revenue: EUR 3,538 million (FY2025, Group); Bioprocess Solutions division EUR 2,865 million.
Relevant products: PEIpro PEI-based transfection reagent for scalable virus production, available in GMP grade; FectoVIR-AAV (GMP) and FectoVIR-LV for AAV and lentiviral vector production; and the legacy jetPEI range for research transfection.
Key developments:
February and December 2022: Polyplus acquired e-Zyvec, then the CDMOs Xpress Biologics (Belgium) and Bio Elpida (France).
March 2023: Sartorius Stedim Biotech agreed to acquire Polyplus for about EUR 2.4 billion; the acquisition was completed in July 2023.
August 2023: Launched the FectoVIR-LV transfection reagent for lentiviral vectors.
September 2025: More than doubled its GMP transfection reagent production site in Illkirch, France, to over 8,000 m².
Strategy: Sartorius aims to build an end-to-end upstream platform for cell and gene therapy manufacturing, combining plasmid DNA, GMP transfection reagents and bioprocess equipment, with PEI-based reagents as a key recurring consumable.
Polysciences, Inc. (Kyfora Bio) (Challenger)
Overview: Polysciences, headquartered in Warrington, Pennsylvania, USA, and founded in 1961, is a specialty chemicals and life-science reagent manufacturer with operations in the United States, Germany and Taiwan. Its linear PEI products are among the most widely cited transfection reagents in research. In 2023 it launched Kyfora Bio to serve GMP bioprocessing customers.
Latest reported revenue: Private; revenue not publicly disclosed.
Relevant products: PEI MAX (linear PEI hydrochloride, MW 40,000, high-potency transfection grade); Transporter 5; MAXgene GMP transfection reagent; and a catalogue of branched and linear PEI grades.
Key developments:
January 2023: Launched the Kyfora Bio bioprocessing brand, operating a 45,000 sq ft cGMP facility in Horsham, Pennsylvania.
December 2024: Kyfora Bio launched the AmpliFect GMP Transfection Enhancer for use with MAXgene GMP PEI workflows in AAV and lentiviral vector production.
Strategy: Polysciences is turning its strong research-grade PEI franchise into a GMP and bioprocessing offer for viral vector manufacturers through Kyfora Bio, supported by distribution through major laboratory supply channels.
Merck KGaA (MilliporeSigma / Sigma-Aldrich) (Challenger)
Overview: Merck KGaA, headquartered in Darmstadt, Germany, and founded in 1668, is a science and technology group with Life Science, Healthcare and Electronics businesses. Its Life Science business, operating as MilliporeSigma in the U.S. and Canada, offers one of the broadest research catalogues of PEI grades worldwide through the Sigma-Aldrich brand.
Latest reported revenue: EUR 21.1 billion (FY2025, Group); Life Science EUR 8.98 billion.
Relevant products: PEI Prime linear PEI, lot-tested for gene delivery; branched PEI (for example, average Mw about 25,000); and a wide range of other branched and linear PEI grades for research and development.
Key developments:
May 2024: Agreed to acquire Mirus Bio, a developer of transfection reagents, for USD 600 million; the acquisition closed in August 2024, strengthening its viral vector bioprocessing offering.
Strategy: Merck KGaA is expanding its upstream viral vector portfolio through acquisitions while using its global catalogue and e-commerce reach to supply PEI to research and process development customers.
Yeasen Biotechnology (Shanghai) Co., Ltd. (Challenger)
Overview: Yeasen Biotechnology, founded in 2014 and headquartered in Shanghai, China, makes life-science enzymes and reagents. It has an ISO 13485 production base in Wuhan and warehousing in the United States and Singapore. It is an emerging supplier of GMP-grade PEI transfection reagents for viral vector manufacturing.
Latest reported revenue: Private; revenue not publicly disclosed.
Relevant products: Linear PEI (MW 25,000 and MW 40,000); Hieff Trans PEI Transfection Reagent, including a GMP grade; and the UltraAAV GMP transfection reagent.
Key developments:
April 2023: Submitted a US FDA Drug Master File (DMF No. 38217) for its PEI Transfection Reagent.
July 2025: Its UltraAAV GMP-grade transfection reagent was accepted into the US FDA DMF system.
Strategy: Yeasen offers cost-competitive GMP-grade transfection reagents with regulatory documentation to Chinese and international AAV and lentiviral vector manufacturers.
Thermo Fisher Scientific Inc. (Niche player)
Overview: Thermo Fisher Scientific, headquartered in Waltham, Massachusetts, USA, was formed in 2006 through the merger of Thermo Electron and Fisher Scientific. It supplies PEI as part of its Thermo Scientific Chemicals research portfolio, which in 2021 brought together the former Alfa Aesar and Acros Organics brands.
Latest reported revenue: USD 44.56 billion (FY2025).
Relevant products: Branched PEI (for example, MW 600 and MW 70,000 as a 30% aqueous solution) and linear PEI (MW 25,000) for research and development.
Key developments:
September 2025: Completed the acquisition of Solventum's Purification & Filtration business for about USD 4.0 billion, strengthening its bioprocessing portfolio.
Strategy: Thermo Fisher supplies PEI as part of a broad research chemicals catalogue through Fisher Scientific's global distribution, while investing heavily in bioprocessing.
FUJIFILM Wako Pure Chemical Corporation (Niche player)
Overview: FUJIFILM Wako Pure Chemical, headquartered in Osaka, Japan, and founded in 1922, has been a subsidiary of FUJIFILM Holdings since 2017. It supplies laboratory chemicals, specialty chemicals and diagnostic reagents, including several PEI grades.
Latest reported revenue: JPY 3,357.0 billion (FUJIFILM Holdings, FY ended March 2026); subsidiary revenue not separately disclosed.
Relevant products: Polyethyleneimine in several average molecular weight grades (for example, about 10,000) and 30% Polyethyleneimine P-70 solution.
Key developments:
May 2023: Established a Pharmaceutical Materials Division.
May 2024: Installed new equipment that tripled its capacity for GMP pharmaceutical raw materials.
Strategy: FUJIFILM Wako is moving from laboratory reagents into GMP-grade materials for pharmaceutical and bioprocessing customers, building on its strong position in Japan and Asia.
Tokyo Chemical Industry Co., Ltd. (TCI) (Niche player)
Overview: Tokyo Chemical Industry, founded in 1946 in Japan, is a research reagent manufacturer with more than 30,000 products and operations in Japan, the United States, Europe, China and India.
Latest reported revenue: Private; revenue not publicly disclosed.
Relevant products: Polyethyleneimine (about 30% in water, CAS 9002-98-6) and several viscosity-graded PEI products for research use.
Key developments:
No PEI-specific developments have been publicly reported since 2022; the company continues to supply PEI through its global research catalogue.
Strategy: TCI serves research-scale PEI demand worldwide through its catalogue and regional distribution centres.
Wuhan Qianglong New Chemical Materials Co., Ltd. (Niche player)
Overview: Wuhan Qianglong New Chemical Materials, based in Wuhan, Hubei Province, China, is identified in Chinese industry sources as one of the country's leading domestic PEI manufacturers, alongside a related entity, Huanggang Qianglong Chemical New Materials. It supplies industrial branched PEI mainly to the Chinese market.
Latest reported revenue: Private; revenue not publicly disclosed.
Relevant products: Industrial branched polyethyleneimine for domestic paper, water treatment, coatings and adhesive applications.
Key developments:
No developments have been publicly reported in English-language sources since 2022.
Strategy: The company concentrates on domestic industrial demand in China, competing with imported product on price and local service.
Threat of New Entrants: Low
Producing ethyleneimine requires specialised containment, permits and safety know-how, which is a major barrier to entry.
Established producers benefit from long customer qualification histories and integrated feedstock supply.
Barriers are lower in the research-grade linear PEI niche, where several reagent suppliers compete, but GMP qualification still takes time.
Bargaining Power of Suppliers: Medium
Ethylene and ethanolamines are widely traded commodities, which limits the power of feedstock suppliers.
Monomer supply is concentrated among a few integrated producers, which strengthens their position over non-integrated converters.
Energy and logistics costs are an important external cost factor, especially in Europe.
Bargaining Power of Buyers: Medium
Large paper groups and water treatment chemical companies buy in volume and can switch to alternative cationic polymers.
Biopharmaceutical buyers of GMP-grade PEI are less price-sensitive, because switching reagents requires process revalidation.
Buyers in specialty niches have few qualified alternative suppliers, which limits their leverage.
Threat of Substitutes: Medium–High
PolyDADMAC, cationic polyacrylamide, polyvinylamine and PAE resins compete in paper and water treatment.
Lipid reagents, electroporation and stable producer cell lines compete with PEI-based transient transfection.
PEI keeps an edge where its unmatched charge density and reactivity are essential.
Competitive Rivalry: Medium
Industrial PEI production is consolidated among a few global producers, which moderates price competition.
Chinese producers are increasing competition in technical grades, especially in Asia Pacific.
Rivalry is stronger in research reagents, where suppliers compete on performance, documentation and service.
Threat of New Entrants: Low; Hazardous monomer handling, permits and qualification barriers.
Bargaining Power of Suppliers: Medium; Commodity feedstocks, but concentrated monomer supply.
Bargaining Power of Buyers: Medium; Large volume buyers in paper and water; less leverage in GMP grades.
Threat of Substitutes: Medium–High; Several alternative cationic polymers and transfection technologies.
Competitive Rivalry: Medium; Consolidated industrial supply; more competition in reagents and Asia.
Market estimates by geography (2032)
InsightAsia Pacific leads with $135.81M by 2032, while Middle East & Africa is projected to grow fastest at a 6.4% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $46.43M | $59.87M | $70.86M | 4.3% | 24% |
| Europe | $46.83M | $59.49M | $69.38M | 4.0% | 23% |
| Asia Pacific | $78.67M | $108.25M | $135.81M | 5.6% | 46% |
| Latin America | $5.31M | $7.43M | $9.45M | 5.9% | 3% |
| Middle East & Africa | $5.23M | $7.51M | $9.74M | 6.4% | 3% |
| Total | $182.48M | $242.55M | $295.24M | 4.9% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$295.24M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Branched | $216.12M | 4.6% | 73% |
| Linear | $79.13M | 6.0% | 27% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Polyethyleneimine Market covering market dynamics, competitive landscape, and strategic outlook.
The Polyethyleneimine Market market is projected to reach $295.24M by 2032, growing at 4.9% CAGR. The Branched segment holds the largest share.
The Global Polyethyleneimine Market is driven by a mix of mature, volume-driven uses and smaller, faster-growing specialty uses. Pulp & paper and general industrial uses provide a stable demand base that tracks industrial activity. Water treatment and gene delivery are expanding faster because of regulation and biopharmaceutical investment. At the same time, the hazardous nature of the ethyleneimine monomer, a concentrated supply base and competition from alternative chemistries limit the pace of growth. This chapter examines these forces.
Growth of Paper-Based Packaging and Tissue Production
Pulp & paper is the largest application, at USD 77.14 Million in 2025. PEI is used in papermaking as a retention and drainage aid, as a fixing agent that neutralises anionic contaminants ("anionic trash"), and as a component of wet-strength systems. Demand is closely linked to output of containerboard, cartonboard and tissue, which continue to grow as e-commerce expands and brand owners replace plastic packaging with fibre-based alternatives. Policy is reinforcing this shift: the EU Packaging and Packaging Waste Regulation and single-use plastics rules in the EU, India and several other markets favour recyclable fibre-based formats. Higher use of recycled fibre also increases the load of dissolved and colloidal contaminants in mill water circuits, which raises demand for highly cationic fixatives such as PEI. Mill investment is concentrated in China, Southeast Asia, India and Brazil, which supports above-average growth in those markets.
Tighter Water Quality and Wastewater Regulation
Water treatment is the second-fastest-growing application, with a CAGR of 5.20% over 2026–2032. PEI's high charge density and chelating amine groups make it effective for flocculating fine particles, binding heavy metals and modifying membranes and adsorbents. Regulators are tightening limits on industrial discharges and drinking water contaminants. Examples include the recast EU Drinking Water Directive (EU) 2020/2184, the revised EU Urban Wastewater Treatment Directive, China's GB 5749-2022 drinking water standard, and the U.S. EPA's 2024 national drinking water regulation for selected PFAS. Water scarcity in the Middle East, India and northern China is also driving investment in water reuse and desalination pre-treatment. Together these trends increase the use of advanced, high-performance treatment chemicals in which PEI is a component.
Expansion of Cell and Gene Therapy Manufacturing
Gene delivery & biotech is the fastest-growing application, rising from USD 33.06 Million in 2025 to USD 50.19 Million in 2032 at a CAGR of 5.97%. Linear PEI is the most widely used chemical reagent for transient transfection of HEK293 and CHO cells, the main production route for adeno-associated virus (AAV) and lentiviral vectors and for rapid recombinant protein expression. The number of approved gene therapies has risen, and many programmes are moving from clinical to commercial scale. As a result, demand is shifting from research-grade PEI to GMP-grade reagents with full traceability, regulatory support files and lot-to-lot consistency. These grades sell at much higher prices than industrial PEI, so value growth in this segment outpaces volume growth. Acquisitions such as Sartorius's purchase of Polyplus show how strategically important transfection reagents have become in bioprocessing.
Demand for High-Performance Adhesion and Coating Chemistries
Within "Others", PEI is used as a primer and adhesion promoter for extrusion coating and lamination of films such as PET, BOPP and aluminium foil, as a curing agent and modifier in epoxy and polyurethane systems, and as a dye-fixing and dispersing agent in inks and textiles. Growth in flexible packaging, especially recyclable mono-material structures that need strong interlayer adhesion without solvent-based primers, supports demand for waterborne PEI primers. Emerging uses in CO₂ capture sorbents, battery binders and electrode coatings, and electronic materials add further, though still small, growth potential.
GMP-Grade Linear PEI for Viral Vector Production
The move of gene therapies into late-stage and commercial manufacturing creates demand for linear PEI made under GMP conditions, with drug master files, animal-origin-free certification and validated impurity profiles. Suppliers that can offer such grades at scale, along with process development support for AAV and lentiviral transfection, can capture premium pricing and long-term supply agreements with biopharmaceutical companies and CDMOs.
Carbon Capture and Environmental Applications
PEI-impregnated silica and other amine-functionalised solid sorbents are among the most studied materials for direct air capture and point-source CO₂ capture, because PEI's dense amine content gives high CO₂ uptake and relatively low regeneration energy. Public funding for carbon removal, including the U.S. Department of Energy's regional direct air capture hubs programme, is accelerating pilot and demonstration projects. PEI-based adsorbents and membranes for heavy-metal and micropollutant removal are a parallel opportunity.
Capacity Investment in High-Growth Emerging Markets
India (CAGR 7.66%), Southeast Asia, the Gulf states and Brazil combine rising paper and packaging output, large water infrastructure programmes and growing biomanufacturing ambitions. Local production, toll manufacturing or distribution partnerships in these regions can reduce logistics costs for a polymer often shipped as a dilute solution, and position suppliers ahead of demand.
Hazardous Monomer and Concentrated Supply Base
Branched PEI is made from ethyleneimine (aziridine), a highly reactive, acutely toxic monomer that is classified as carcinogenic and mutagenic. In the U.S., occupational exposure is governed by a dedicated OSHA standard. Producing and handling the monomer requires specialised containment, permitting and safety systems, so only a few companies make it. This concentration creates supply risk: an outage at a single plant can tighten global availability and raise prices. It also discourages new entrants and limits the speed at which capacity can follow demand.
Competition from Alternative Chemistries
In paper and water treatment, PEI competes with lower-cost cationic polymers, including cationic polyacrylamides, polyDADMAC, polyamines, polyvinylamine and PAE resins, which can deliver similar performance in many applications. In gene delivery, lipid-based transfection reagents, electroporation and stable producer cell lines offer alternatives to PEI-mediated transient transfection. The latter are increasingly adopted for late-stage and commercial manufacturing because they can reduce reagent costs and variability. These substitutes put a ceiling on PEI pricing in commodity uses.
Structural Decline in Graphic Paper
Demand for printing and writing paper continues to fall in North America, Europe and Japan as communication shifts to digital channels, leading to mill closures and conversions. This limits volume growth in the largest application in mature markets: pulp & paper grows at 2.70% in North America and 2.51% in Europe, against a global segment CAGR of 3.20%.
Challenge: Regulatory Scrutiny and Toxicological Profile
PEI polymers have low residual monomer content, but the hazard profile of ethyleneimine and the cytotoxicity of high-molecular-weight PEI in biomedical uses attract regulatory and customer scrutiny. Food-contact, drinking-water and pharmaceutical uses require specific approvals and documentation, which raises compliance costs and lengthens qualification cycles.
Challenge: Price and Supply Volatility
PEI prices are exposed to the cost of ethylene, ethanolamines and energy, and to freight costs for products often shipped as aqueous solutions. Energy price swings in Europe since 2022 and periodic logistics disruptions have shown how quickly margins and availability can change, prompting buyers to diversify suppliers and hold higher safety stocks.
Trend: Shift Toward High-Purity, Defined-Molecular-Weight Grades
Customers in life sciences, electronics and advanced materials increasingly require PEI with narrow molecular weight distributions, low residual monomer and documented impurity profiles. Producers are responding with dedicated product lines, which is shifting the value mix toward specialty grades.
Trend: Sustainability and Water-Based Formulations
Converters and formulators are replacing solvent-borne primers and coatings with waterborne systems to reduce VOC emissions and support recyclability. Water-soluble PEI fits this shift well. Producers are also publishing product carbon footprints and exploring renewable or mass-balance feedstocks for ethanolamine-based value chains.
The PEI value chain runs from petrochemical feedstocks to a diverse group of industrial and life-science users. Value is added mainly at the monomer and polymerisation stages, which need specialised technology and safety infrastructure, and in the final purification and qualification of high-purity grades.
PEI is regulated both as a polymer in its own right and through rules on its monomer, ethyleneimine (aziridine). In the United States, the FDA explicitly lists polyethylenimine in its indirect food additive regulations for paper and adhesives. Occupational exposure to the monomer is governed by OSHA's ethyleneimine standard, and ethyleneimine is listed as a hazardous air pollutant under the Clean Air Act. In the European Union, PEI and ethyleneimine are subject to REACH and CLP, and ECHA's 2024 assessment of the aziridines group signals possible further regulatory action. Ethyleneimine is also on the EU positive list of starting substances for materials in contact with drinking water. In Asia, chemical inventory and new-substance rules in China and Japan govern manufacture and import. Life-science grades used in gene therapy manufacturing are subject to GMP and ancillary-material quality expectations set by medicines regulators.
Feb 2022: Polyplus (now Sartorius); Acquisition; Acquired e-Zyvec, a specialist in custom DNA vector design.
Dec 2022: Polyplus (now Sartorius); Acquisition; Acquired Xpress Biologics (Belgium) and Bio Elpida (France), plasmid and protein CDMOs.
Jan 2023: Polysciences; Launch / Expansion; Launched Kyfora Bio, its cGMP bioprocessing brand with a 45,000 sq ft facility in Horsham, Pennsylvania.
Mar 2023: Sartorius Stedim Biotech; Acquisition; Agreed to acquire Polyplus, a leading supplier of PEI-based transfection reagents, for about EUR 2.4 billion.
Apr 2023: Nippon Shokubai; Restructuring; Reorganisation took effect, including a new Water & Environment Solutions business department.
Apr 2023: Yeasen Biotechnology; Regulatory filing; Submitted US FDA Drug Master File No. 38217 for its PEI Transfection Reagent.
May 2023: FUJIFILM Wako; Organisation; Established a Pharmaceutical Materials Division.
Jul 2023: Sartorius; Acquisition; Completed the acquisition of Polyplus.
Aug 2023: Polyplus (Sartorius); Product launch; Launched the FectoVIR-LV transfection reagent for lentiviral vector production.
May 2024: FUJIFILM Wako; Expansion; Tripled its production capacity for GMP pharmaceutical raw materials.
Aug 2024: Merck KGaA; Acquisition; Closed the USD 600 million acquisition of Mirus Bio, a developer of transfection reagents (agreement signed May 2024)
Sep 2024: BASF; Strategy; Launched its "Winning Ways" strategy, designating Nutrition & Care (home of Lupasol) as a core business.
Dec 2024: Polysciences (Kyfora Bio); Product launch; Launched the AmpliFect GMP Transfection Enhancer for MAXgene GMP PEI workflows.
Apr 2025: Nippon Shokubai; Strategy; Announced Mid-Term Management Plan 2027 with JPY 245 billion capex and a focus on Solutions businesses.
Jul 2025: Yeasen Biotechnology; Regulatory filing; Its UltraAAV GMP-grade transfection reagent was accepted into the US FDA DMF system.
Sep 2025: Sartorius Stedim Biotech; Expansion; More than doubled its GMP transfection reagent production site in Illkirch, France, to over 8,000 m².
Political
Industrial policy in China, India and the Gulf states promotes domestic chemical and biomanufacturing capacity, which supports local PEI demand and production.
Trade tensions and tariffs on chemicals between the U.S., China and other economies affect cross-border PEI and monomer flows.
Public funding for gene therapy research and biomanufacturing resilience supports demand for transfection reagents.
Economic
Industrial production and packaging demand drive volume in paper and general industrial uses.
Ethylene, ethanolamine and energy price volatility affects production costs, especially in Europe.
Biopharmaceutical funding cycles affect demand for research and GMP-grade linear PEI.
Social
Consumer preference for sustainable, plastic-free packaging supports fibre-based packaging and PEI demand in papermaking.
Growing public concern over water quality and contaminants raises investment in advanced treatment.
Wider access to advanced therapies is increasing the patient base for gene therapies.
Technological
Advances in AAV and lentiviral process development are raising transfection efficiency and the need for optimised PEI grades.
Research on PEI-based CO₂ sorbents, membranes and battery materials is opening new applications.
Improved synthesis and purification methods allow narrower molecular weight distributions and lower residual monomer.
Environmental
Stricter wastewater discharge standards increase demand for high-performance flocculants and metal-binding agents.
Pressure to reduce the carbon footprint of chemical production is pushing producers toward renewable energy and alternative feedstocks.
PEI's aquatic toxicity requires careful management of discharges and spills.
Legal
REACH, TSCA, China's new chemical substance rules and Japan's CSCL govern production, import and use.
Food-contact regulations govern PEI use in paper and packaging adhesives.
GMP and pharmaceutical quality requirements govern reagents used in gene therapy manufacturing.
Profiles of 27 companies operating in the Polyethyleneimine Market market, including revenue, employee count, and market positioning where available.
Showing 27 of 27 companies
BASF is the world's largest chemical company by sales, built on the Verbund principle of physically and energetically integrated production sites that turn a handful of feedstocks into thousands of products. Since September 2024 it has run under the "Winning Ways" strategy, which splits the portfolio into four core segments (Chemicals, Materials, Industrial Solutions, Nutrition & Care) that stay integrated, and standalone businesses (Agricultural Solutions, Battery Materials, Environmental Catalyst and Metal Solutions, and the now-divested Coatings) that are being monetized or prepared for capital-market options. In 2025 it generated €59.7 billion in sales and €6.6 billion in EBITDA before special items, a cyclical trough. In 2026 it closed the €7.7 billion Coatings transaction, started up its €-multi-billion Zhanjiang Verbund site, raised earnings guidance, and approached Evonik about a takeover. The investment debate is whether structural cost cuts and portfolio proceeds can restore returns above the cost of capital. --- **The company's own description.** BASF describes its purpose with the line "we create chemistry for a sustainable future" (BASF news release boilerplate, 2026) and states its ambition to be the preferred chemical company for enabling customers' green transformation. It reports around 108,000 employees, customers in nearly every sector and almost every country, and sales of around €60 billion in 2025. The portfolio is described as four core segments plus standalone businesses bundled in Surface Technologies and Agricultural Solutions. **Independent characterization.** BASF is best understood as three businesses under one roof: 1. **An integrated commodity and intermediates engine** (Chemicals, the Monomers half of Materials). This is a steam-cracker-to-derivatives chain selling ethylene and propylene derivatives, isocyanates, polyamide precursors and intermediates on spread economics. Earnings are driven by feedstock and energy costs, operating rates and regional supply-demand. It is the most capital-intensive part of the group and the main source of the 2023–2025 earnings decline: Chemicals EBITDA before special items fell from €1,342 million in 2024 to €853 million in 2025 (Factsheet FY2025). 2. **Formulated and performance products** (Performance Materials, Industrial Solutions, Nutrition & Care). These sell on specification and performance to automotive, construction, packaging, consumer goods, pharma and nutrition customers. Margins are steadier but have come under pressure from Asian competition and, in Care Chemicals, from consumer trading-down to private-label products (Factsheet FY2025 commentary). 3. **Standalone franchises** with different industry logic: Agricultural Solutions (crop protection, seeds and traits, digital farming), ECMS (emissions catalysts plus precious-metal trading and recycling) and Battery Materials. Agricultural Solutions is the group's highest-margin segment at 21.7% EBITDA margin before special items in FY2025 and the largest single earnings contributor at €2,081 million. **Revenue model.** Revenue is almost entirely product sales under supply contracts and spot transactions. There is no subscription model of consequence; digital farming (xarvio) and licensing of process technology and catalysts are small. Seeds and traits include royalty and licensing income within Agricultural Solutions, not separately disclosed. Precious-metal trading inflates ECMS sales (€7,978 million in FY2025) with pass-through metal value, which is why BASF quotes group margins both including and excluding metals (12.3% excluding metals in FY2025 per the CFO on the February 27, 2026 call, versus 11.0% reported). **Value chain position.** Upstream to midstream in petrochemicals with captive crackers at Ludwigshafen, Antwerp, Port Arthur (joint venture with TotalEnergies), Nanjing (joint venture with Sinopec) and Zhanjiang; midstream to downstream in engineering plastics, polyurethane systems, dispersions, additives, surfactants and vitamins; branded and channel-driven in agriculture. BASF exited upstream oil and gas operations when Wintershall Dea's E&P business was transferred to Harbour Energy in September 2024. **Customers and end-markets.** BASF serves industrial customers in chemicals and plastics, transportation, construction, consumer goods, agriculture, electronics, energy and resources, and health and nutrition. Intersegment transfers are large (Chemicals transferred €3,432 million internally in FY2025 on €10,055 million of third-party sales), which shows how much of the upstream output feeds BASF's own downstream chains.
DuPont de Nemours today is a focused, roughly USD 7 bn-revenue multi-industry company. It is no longer the diversified chemical conglomerate of its heritage. After a decade of portfolio surgery, the company consists of two segments: **Healthcare & Water Technologies (about 47% of FY2025 sales):** Tyvek® medical packaging and protective garments, specialty medical device components (Spectrum, Donatelle), and the FilmTec™ / Amberlite™ water purification franchise. **Diversified Industrials (about 53%):** Building envelope products (Tyvek® house wrap, Styrofoam™, Corian®) and engineered industrial technologies (Molykote®, Vespel®, Betaseal™/Betaforce™ adhesives, Cyrel® printing plates). The company earns a premium-specialty margin profile: operating EBITDA margin was 23.8% in FY2025, with guidance of about 24.5% for FY2026. Management targets 3–4% organic growth, 150–200 bps of margin expansion and 8–10% adjusted EPS CAGR through 2028, supported by a lightly levered BBB+/Baa1 balance sheet. The principal overhang is legacy PFAS liability, shared with Chemours, Corteva and Qnity under contractual arrangements. The principal opportunity is a cleaner, higher-growth healthcare/water mix and capital redeployment. --- **Company's own description (FY2025 10-K, Item 1).** DuPont describes itself as a leading provider of advanced solutions that improve everyday life across healthcare, water, construction and industrial markets. It emphasizes helping customers advance their technology pipelines, from clean water to medical packaging that enhances safety and performance. It names its competitive strengths as: - proprietary product and process technologies; - robust application-development pipelines; - well-known brands; - customer intimacy; - global manufacturing and local service capability. **Independent characterization.** DuPont is now best understood as a specialty engineered-materials and components company with four businesses of roughly comparable scale: **Business model and revenue model.** - Revenue is overwhelmingly product sales: materials, components, membranes, resins, garments and plates. Some engineered systems and modules are sold in Water. - There is no material subscription or licensing revenue. Trade secrets may be licensed occasionally (10-K, Intellectual Property). - The contract manufacturing and design services of Spectrum and Donatelle (medical devices) add a design-in / build-to-print services element, but are recognized as product revenue. - Seasonality: North American Building Technologies demand peaks in Q2–Q3. **Value-chain position.** DuPont sits mid-stream as a Tier-1/Tier-2 supplier. It converts purchased raw materials (polyolefins, specialty monomers, resins, silicones, polymers) into engineered materials, membranes and components. These are specified into customers' finished products: medical devices, sterile packaging, water plants, building envelopes, aircraft, vehicles and print packaging. **Customer types.** - Medical device OEMs and sterile packaging converters - Biopharma manufacturers - Industrial end users and EPC/OEM water-system integrators - Municipalities and desalination operators (via integrators) - Builders, contractors and distributors (e.g., Corian® distribution through Hallmark and Parksite) - Automotive and EV OEMs and Tier-1s - Aerospace OEMs - Printing and packaging converters Most products are sold through DuPont's own sales organization, with distributors used for some lines (10-K, Distribution). **End markets.** Healthcare (medical devices, packaging, biopharma, PPE), water (industrial, municipal/desalination, life sciences, microelectronics UPW), construction (residential, non-residential, repair/remodel) and industrial (aerospace, automotive/EV, printing and packaging, general industrial).
Nippon Soda is a mid-cap, diversified Japanese chemical group founded in 1920 as a chlor-alkali producer and progressively re-shaped into a portfolio anchored by two high-value franchises: research-based crop protection (Agri Business, 35% of FY3/26 sales) and specialty "Chemical Materials" (25%), complemented by lower-margin but stable trading/logistics, plant engineering and environmental-recycling businesses. Its crown jewels are niche, high-barrier products in which it holds globally relevant positions — the pharmaceutical excipient NISSO HPC (hydroxypropyl cellulose), liquid polybutadiene NISSO-PB for AI-server copper-clad laminates, KrF photoresist polymer VP-POLYMER, and proprietary agrochemicals such as Mospilan (acetamiprid) and Topsin-M. With FY3/26 net sales of JPY 152.1 billion, record net profit of JPY 18.3 billion, an equity ratio of ~66.6%, and a 50%+ total shareholder return policy, the company is a conservatively financed, R&D-led specialty player now pivoting toward healthcare (including animal health) and advanced ICT materials under its Stage III plan to FY3/30. --- ### Company's own description According to its Stage III medium-term plan (May 2026), Nippon Soda describes its mission as creating new value through the power of chemistry, and frames the group as supporting everyday life through chemical products and services across four "material" fields: Agriculture (securing food and sustainable agriculture), Healthcare (healthy life for all people), Environment (toward a resource-recycling society) and ICT (chemical functions for IT devices). The Yuho describes the parent's business as manufacturing, processing and marketing of industrial chemicals, synthetic resins and plastics, dyes, pharmaceuticals, agrochemicals, veterinary pharmaceuticals and other chemical products. ### Business model and revenue model Nippon Soda's revenue is overwhelmingly product-based (manufactured chemical sales), with secondary service revenues from logistics (warehousing, transport, customs brokerage), engineering/EPC contracts and waste treatment. There is no material subscription revenue. Licensing/active-ingredient supply is embedded in Agri Business: the company supplies proprietary active ingredients (AIs) to global majors and sells formulated products through its own overseas network and partners. The revenue mix by nature (approximation from FY3/26 segment data; company does not disclose a product/service split): *Note: the above split is an analytical characterization; the company does not report revenue by nature.* ### Value-chain position **Agri Business:** fully integrated R&D-type agrochemical originator — chemical synthesis, biological/safety research, formulation research, field evaluation, AI manufacturing (including via Nisso Namhae Agro in Korea) and formulation, registration and global marketing (Stage III plan). The company emphasizes that R&D-type agrochemical originators are largely limited to five overseas majors plus Japanese firms, and that Japanese originators punch above their weight in new AI discovery. **Chemical Materials:** upstream chlor-alkali (caustic soda, chlorine, hydrochloric acid) feeding downstream fine/specialty chemistry (living anionic polymerization for NISSO-PB and VP-POLYMER; cellulose derivatization for HPC; penem API synthesis). **Trading & Logistics:** captive and third-party distribution (Nisso Shoji) and specialized hazardous/pharma logistics (Sanwa Soko, Sanso Unyu). **Engineering:** fine-chemical-type EPC (Nisso Engineering) and civil works (Nisso Kensetsu). **Eco Solutions:** waste treatment, zinc recovery from electric-arc-furnace dust, sulfuric acid recycling (Nisso Metallochemical). ### Customer types and end-markets Customers include global agrochemical majors and distributors, farmers' cooperatives (via channels), generic and innovator pharmaceutical companies and supplement makers (HPC, SSF, faropenem API), copper-clad-laminate (CCL) and semiconductor-materials producers (NISSO-PB, 1,2-SBS, VP-POLYMER), thermal-paper manufacturers (color developers), battery-materials producers, industrial users of commodity chemicals, steelmakers (EAF dust treatment), and public/private construction clients (Engineering). End-markets: crop protection (fruit & vegetables first, expanding to grains), pharmaceuticals/nutraceuticals, semiconductors/electronics (AI servers, HBM, automotive chips), infrastructure, and environmental services. ### Independent characterization Nippon Soda is best understood as two engines and three stabilizers. The engines — Agri Business and specialty Chemical Materials — generated roughly 75% of FY3/26 segment operating profit (JPY 11.2 billion of JPY 14.97 billion before adjustments) on 60% of sales. Agri is cyclical and FX-sensitive (65.7% overseas sales ratio in FY3/26), while Chemical Materials has been structurally re-rated from a ~5–6% margin business to ~15–17% after exiting commodity lines (metallic sodium via Alkaline S.A.S., NISSO HI-CHLON, phenol-based color developers, sodium cyanide). The stabilizers (Trading & Logistics, Engineering, Eco Solutions) are low-growth and modest-margin but add scale and cash. A further, often-overlooked profit pillar is equity-method income (JPY 6.06 billion in FY3/26, chiefly Iharabras in Brazil), which made ordinary profit (JPY 22.99 billion) much larger than operating profit and is highly FX-sensitive (BRL/USD).
RPM International is a holding company for more than a dozen semi-autonomous specialty-chemicals franchises. These businesses make coatings, sealants, roofing, concrete admixtures, flooring, fireproofing and building-envelope systems, mostly for maintenance, repair and restoration rather than new construction. Its brand portfolio is unusually deep for a USD 7.9 billion company: Rust-Oleum, DAP, Zinsser, Varathane and The Pink Stuff on the consumer side; Tremco, Euclid, Dryvit, Nudura, Kalzip, Stonhard, Carboline and Fibergrate on the professional side. Each brand holds a leading position in a niche that larger diversified coatings groups do not dominate. Since 2018 RPM has run successive operational-improvement programs (MAP to Growth, MAP 2025, and now "MAP 3.0"). These have lifted gross margin from about 36% (FY2022) to about 41% (FY2026) and moved the group from a loose federation toward a centrally coordinated operating company. RPM is a disciplined, dividend-growing compounder with 52 consecutive annual dividend increases. Its growth vectors are engineered building systems, emerging markets (the "Platform" model) and bolt-on M&A. --- ### Company's own description (FY2026 Form 10-K, Item 1) RPM describes itself as follows: its subsidiaries manufacture, market and sell specialty chemical product lines, including high-quality specialty paints, infrastructure rehab and repair products, protective coatings, roofing systems, sealants and adhesives. These products focus on the maintenance and improvement needs of the construction, industrial, specialty and consumer markets. Footprint as of 31 May 2026: - Products marketed in about 167 countries and territories. - Manufacturing in about 120 locations across 22 countries. - About 31% of sales generated internationally: foreign operations 29.8% of net sales, plus direct U.S. exports of 0.9%. The press-release boilerplate calls RPM "a world leader in specialty coatings, sealants, building materials and related services." ### Business model RPM's model has four defining features. - **Decentralised entrepreneurial structure, becoming more integrated.** The founder's philosophy, still quoted in the 2026 proxy, is: "Hire the best people you can find. Create an atmosphere that will keep them. Then let them do their jobs." Operating companies historically kept their own brands, sales forces and ERP systems. The MAP programs are deliberately centralising procurement, manufacturing, accounting and IT. The stated goal is to consolidate more than 75 ERP systems to one platform per segment (Q4 FY2026 8-K). **Repair and maintenance bias:** Much of the portfolio serves existing assets: roof restoration, re-cover, concrete repair, corrosion control, rust prevention and DIY touch-up. That demand is less cyclical than new-build construction. The FY2026 10-K notes that re-roofing has historically accounted for over three-quarters of U.S. roofing demand. **Systems and turnkey selling:** In CPG and PCG, RPM increasingly sells integrated systems (the "Power of One" building envelope) and supply-and-apply turnkey services. Examples include Stonhard flooring installation and Weatherproofing Technologies roofing services. This captures more of each construction project's spend. **Bolt-on M&A plus organic growth:** RPM completed six acquisitions in each of FY2025 and FY2026 (FY2026 10-K Note F). ### Revenue model mix | Revenue type | Characterisation | Evidence | |---|---|---| | Product sales | Dominant (estimated well above 90% of revenue; exact split not publicly disclosed) | Manufactured coatings, sealants, admixtures and similar products sold through retail, distribution and direct channels | | Installation and services | Material within CPG and PCG; not separately disclosed | WTI/WTC roofing services, turnkey general contracting, TremCare maintenance programs, Stonhard installed flooring, Legend Brands/RoofTec restoration services, Pure Air Control Services | | Warranty and extended programs | Embedded in pricing; generates deferred revenue | Current unearned revenue USD 75.3M and long-term unearned revenue USD 92.4M at FY2026 (standardized balance sheet) | | Licensing and royalties | Minor | The 10-K notes license fees and royalty income from numerous international license agreements, plus equity-method joint ventures | | Subscription | None identified | — | RPM does not disclose a product versus service versus licensing split. From filings, the mix is: ### Value-chain position RPM is a formulator and brand owner, positioned downstream of commodity chemical producers. It buys petroleum-derived resins, solvents, pigments, minerals, metals and packaging (FY2026 10-K, Raw Materials). It is selectively backward-integrated: RPM cites expanding in-house raw material production, and Arnette Polymers makes amine curing agents and epoxy intermediates. Channels downstream include: - Mass merchants and home centres, where the single largest Consumer customer was 20% of Consumer sales in FY2026. - Hardware and paint stores. - Distributors. - Contractors and specifiers. - Direct sales to industrial plant owners, public institutions and infrastructure agencies. ### Customer types and end markets | End market | Segment exposure | Representative brands | |---|---|---| | Commercial / institutional building envelope (roofing, walls, waterproofing, sealants) | CPG | Tremco, Dryvit, Nudura, illbruck, Kalzip, Volteco | | Concrete, cement and infrastructure | CPG, PCG | Euclid, Toxement, Viapol, Prime Resins, Fibrecrete | | Industrial maintenance, oil and gas, petrochemical, power, data centres | PCG | Carboline, Stonhard, Fibergrate, Nullifire | | Food and pharma | PCG | Mantrose-Haeuser, NatureSeal, Profile Food Ingredients | | Marine, wood finishes, powder coatings | PCG | Pettit, Woolsey, FinishWorks/Mohawk, TCI | | Residential DIY and professional painters | Consumer | Rust-Oleum, Zinsser, Varathane, DAP | | Household cleaning | Consumer | The Pink Stuff, Krud Kutter, Mean Green | | Pigments, colorants, OEM and personal care | Consumer (Color Group) | Day-Glo | | Restoration services equipment | CPG (Legend Brands) | Dri-Eaz, Sapphire Scientific | ### Independent characterisation RPM is best understood as a portfolio of niche category leaders with a structural margin-improvement story layered on top. The professional segments (CPG and PCG) are about 66% of sales and supply the growth. In FY2026 they posted record results driven by high-performance buildings, data centres, infrastructure, fireproofing and concrete admixtures. In Q1 FY2027, emerging-market regions grew more than 20%. The Consumer segment is about 34% of sales. It is a cash-generative but volume-challenged DIY business. Organic Consumer sales fell 0.8% in Q4 FY2026 and 4.7% in Q2 FY2026. They recovered to +5.2% in Q1 FY2027 on shelf-space wins and pricing. The equity debate therefore centres on three questions: 1. Can MAP savings and pricing protect margins against renewed raw-material inflation linked to the Middle East conflict? 2. Is the Q1 FY2027 CPG slowdown temporary? 3. Will the 9 November 2026 investor day credibly frame the next margin plan?
3 interactive charts drawn from the Polyethyleneimine Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Polyethyleneimine Market By Application
Global Polyethyleneimine Market By Product Type
Global Polyethyleneimine Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and forecast (2022–2032, USD Million)
Market Size (USD Million)
